Two Sigma Investments LP Sells 135,725 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Two Sigma Investments LP reduced its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 33.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 271,776 shares of the company's stock after selling 135,725 shares during the period. Two Sigma Investments LP owned 0.27% of Day One Biopharmaceuticals worth $3,443,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of DAWN. R Squared Ltd bought a new position in Day One Biopharmaceuticals during the 4th quarter worth $31,000. China Universal Asset Management Co. Ltd. raised its position in Day One Biopharmaceuticals by 11.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,383 shares of the company's stock worth $271,000 after purchasing an additional 2,180 shares during the last quarter. Handelsbanken Fonder AB raised its position in Day One Biopharmaceuticals by 16.7% during the 4th quarter. Handelsbanken Fonder AB now owns 31,500 shares of the company's stock worth $399,000 after purchasing an additional 4,500 shares during the last quarter. Bank of New York Mellon Corp raised its position in Day One Biopharmaceuticals by 43.4% during the 4th quarter. Bank of New York Mellon Corp now owns 244,829 shares of the company's stock worth $3,102,000 after purchasing an additional 74,091 shares during the last quarter. Finally, Fisher Asset Management LLC raised its position in Day One Biopharmaceuticals by 21.6% during the 4th quarter. Fisher Asset Management LLC now owns 89,132 shares of the company's stock worth $1,129,000 after purchasing an additional 15,831 shares during the last quarter. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Price Performance

Shares of DAWN traded down $0.03 during trading hours on Tuesday, hitting $6.98. The stock had a trading volume of 1,709,445 shares, compared to its average volume of 1,123,272. The firm has a 50 day simple moving average of $6.99 and a 200-day simple moving average of $10.08. The firm has a market capitalization of $707.51 million, a P/E ratio of -6.78 and a beta of -1.24. Day One Biopharmaceuticals, Inc. has a 1-year low of $6.08 and a 1-year high of $16.76.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.11. The firm had revenue of $30.76 million during the quarter, compared to analyst estimates of $30.28 million. Equities analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. HC Wainwright reissued a "buy" rating and issued a $36.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, April 3rd. Wedbush reissued an "outperform" rating and issued a $25.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, May 7th. Needham & Company LLC lowered their price objective on Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. JPMorgan Chase & Co. lowered their price objective on Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a research report on Wednesday, March 5th. Finally, The Goldman Sachs Group lowered their price objective on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a research report on Tuesday, March 25th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $30.57.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, CEO Jeremy Bender sold 13,964 shares of the business's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $6.26, for a total value of $87,414.64. Following the transaction, the chief executive officer now owns 145,737 shares in the company, valued at $912,313.62. The trade was a 8.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Charles N. York II sold 4,282 shares of the business's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $6.26, for a total value of $26,805.32. Following the completion of the transaction, the chief financial officer now owns 265,231 shares in the company, valued at $1,660,346.06. The trade was a 1.59% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 26,725 shares of company stock worth $167,299. Insiders own 6.20% of the company's stock.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.